<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link brand__border-color" href="/government/organisations/nhs-commissioning-board">
      <span class="gem-c-organisation-logo__name">NHS England</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Introduction
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 17 March 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav aria-label="Contents" class="gem-c-contents-list" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-label="#related-documents" data-track-options="{&quot;dimension29&quot;:&quot;\n1. Related documents&quot;}" href="#related-documents"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Related documents</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-category="contentsClicked" data-track-label="#haemoglobinopathies" data-track-options="{&quot;dimension29&quot;:&quot;\n2. Haemoglobinopathies&quot;}" href="#haemoglobinopathies"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">Haemoglobinopathies</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#sickle-cell-disease" data-track-options="{&quot;dimension29&quot;:&quot;\n3. Sickle cell disease&quot;}" href="#sickle-cell-disease"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">Sickle cell disease</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 4" data-track-category="contentsClicked" data-track-label="#beta-thalassaemia-major" data-track-options="{&quot;dimension29&quot;:&quot;\n4. Beta thalassaemia major&quot;}" href="#beta-thalassaemia-major"><span class="gem-c-contents-list__number">4. </span><span class="gem-c-contents-list__numbered-text">Beta thalassaemia major</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 5" data-track-category="contentsClicked" data-track-label="#screening-support-service" data-track-options="{&quot;dimension29&quot;:&quot;\n5. Screening support service&quot;}" href="#screening-support-service"><span class="gem-c-contents-list__number">5. </span><span class="gem-c-contents-list__numbered-text">Screening support service</span></a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/sct-screening-handbook-for-antenatal-laboratories/introduction
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<p>This guidance describes the requirements for laboratories involved in antenatal screening and referral of antenatal samples to DNA laboratories.</p>

<p>Laboratories must check this section information frequently. The guidance and requirements described relate to a screening programme, not a diagnostic service.</p>

<p>Sickle cell and thalassaemia (<abbr title="sickle cell and thalassaemia">SCT</abbr>) screening laboratories must:</p>

<ul>
  <li>be accredited by the UK Accreditation Service (UKAS) to ISO <a class="govuk-link" href="https://www.iso.org/standard/56115.html" rel="external">Medical laboratories – requirements for quality and competence (ISO 15189:2012)</a>
</li>
  <li>meet screening programme quality assurance <a class="govuk-link" href="https://www.gov.uk/government/publications/antenatal-and-newborn-screening-laboratory-quality-assurance">(<abbr title="quality assurance">QA</abbr>) requirements mapped to ISO 15189:2012</a>
</li>
  <li>participate in external quality assurance (<abbr title="external quality assurance">EQA</abbr>) schemes accredited to <a class="govuk-link" href="https://www.iso.org/standard/29366.html" rel="external">ISO Conformity assessment. General requirements for proficiency testing schemes (ISO 17043:2010)</a>
</li>
  <li>use ISO 15189:2012 accredited reference laboratories</li>
</ul>

<p>UKAS looks at ISO 15189:2012 and the screening requirements on behalf of regional screening quality assurance services (<abbr title="screening quality assurance service">SQAS</abbr>) and the national screening programme.</p>

<p><a class="govuk-link" href="https://www.gov.uk/guidance/nhs-population-screening-explained">NHS population screening explained</a> sets out the general principles of screening.</p>

<h2>
<span class="number">1. </span>Related documents</h2>

<p>This handbook for antenatal laboratories is part of a suite of documents.</p>

<p>The <a class="govuk-link" href="https://www.gov.uk/government/publications/handbook-for-sickle-cell-and-thalassaemia-screening"><abbr title="sickle cell and thalassaemia">SCT</abbr> screening programme handbook</a> provides operational guidance and information for all practitioners involved in screening.</p>

<p>The <a class="govuk-link" href="https://www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-pathway-requirements-specification"><abbr title="sickle cell and thalassaemia">SCT</abbr> screening pathway requirements specification</a> provides an overview of <abbr title="sickle cell and thalassaemia">SCT</abbr> screening by describing what should happen at each stage of the end-to-end pathway.</p>

<p>The <a class="govuk-link" href="https://www.gov.uk/government/publications/sickle-cell-and-thalassaemia-screening-programme-standards"><abbr title="sickle cell and thalassaemia">SCT</abbr> screening programme standards</a> define a set of standards providers have to meet to make sure local <abbr title="sickle cell and thalassaemia">SCT</abbr> screening services are safe and effective.</p>

<p>Providers must comply with <a class="govuk-link" href="https://www.gov.uk/government/publications/managing-safety-incidents-in-nhs-screening-programmes">national guidance for the management of safety concerns and incidents in screening programmes</a> and NHS England guidance for the management of serious incidents.</p>

<p>The British Committee for Standards in Haematology (<abbr title="British Committee for Standards in Haematology">BCSH</abbr>) has published guidance about screening<sup role="doc-noteref"><a class="govuk-link" href="#fn:1" rel="footnote">[footnote 1]</a></sup>.</p>

<h2>
<span class="number">2. </span>Haemoglobinopathies</h2>

<p>Haemoglobinopathies are a heterogeneous group of more than 1,000 mutations, which are categorised into 2 main groups:</p>

<ul>
  <li>haemoglobin variants</li>
  <li>thalassaemias</li>
</ul>

<p>The haemoglobin variants arise from an alteration in the globin protein structure. The thalassaemias arise from inadequate production of structurally normal globin. There are also thalassaemic haemoglobinopathies that are produced when a structurally abnormal haemoglobin is synthesised at a reduced rate, for example haemoglobin E (<abbr title="haemoglobin E">HbE</abbr>).</p>

<p>The frequency of different haemoglobinopathies varies in different ethnic groups and certain haemoglobinopathies are often associated with a family history. It is important to remember that no haemoglobinopathy is exclusive to any single ethnic group, so all individuals are theoretically at risk.</p>

<p>It is not unusual for people to inherit more than one haemoglobin mutation. Many haemoglobin mutations have no associated clinical significance. Others are associated with severe morbidity and mortality, most notably sickle cell disease and beta (β) thalassaemia major. Changing treatment options including new drug regimes, improved bone marrow transplant (<abbr title="bone marrow transplant">BMT</abbr>) protocols and gene therapy have the potential to significantly improve patient outcomes. Carriers of a haemoglobin mutation are usually asymptomatic.</p>

<h2>
<span class="number">3. </span>Sickle cell disease</h2>

<p>Sickle haemoglobin (<abbr title="sickle haemoglobin">HbS</abbr>) is a haemoglobin variant in which valine replaces glutamic acid, which is the sixth amino acid in the β globin chain. Other much rarer haemoglobins are reported that have this same glutamic acid to valine substitution, but also an additional substitution in cis. All these variants will cause sickle cell disease in the situations described below for <abbr title="sickle haemoglobin">HbS</abbr>.</p>

<p>Sickle cell disease results from the inheritance of certain genotypes, including:</p>

<ul>
  <li>homozygosity for <abbr title="sickle haemoglobin">HbS</abbr> (sickle cell anaemia)</li>
  <li>compound heterozygosity for <abbr title="sickle haemoglobin">HbS</abbr> and an interacting mutation, such as HbC (Hb SC disease)</li>
  <li>β thalassaemia (Hb S/β thalassaemia)</li>
</ul>

<p>The sickling conditions are associated with severe life-threatening vaso-occlusive crises, overwhelming sepsis, splenic sequestration, aplastic crises, stroke, priapism, pulmonary hypertension, proliferative retinopathy, chronic organ damage and avascular necrosis of the hips and shoulders.</p>

<h2>
<span class="number">4. </span>Beta thalassaemia major</h2>

<p>Beta thalassaemias are a group of hereditary conditions that result in reduced (β<sup>+</sup>) or absent (β<sup>0</sup>) synthesis of β globin chains. These are an essential component of the main adult haemoglobin, HbA.</p>

<p>Beta thalassaemias are usually caused by point mutations, small insertions or deletions and, less frequently, large deletions of the β globin gene located on chromosome 11. Inheritance is predominantly autosomal recessive although some dominant mutations have been reported.</p>

<p>Mutation type and inheritance patterns result in variable phenotypes, which range from severe transfusion-dependent anaemia (beta thalassaemia major) to clinically asymptomatic carriers. Lifelong transfusion treatment has associated complications of iron overload, including endocrine dysfunction, cardiomyopathy, liver fibrosis and cirrhosis. A demanding daily regime of therapy with iron chelators that enable iron excretion from the body is required to treat these complications. Insufficient red cell replacement results in symptoms of anaemia, jaundice, poor growth and muscular development and skeletal changes from expansion of the bone marrow due to extramedullary haemopoiesis.</p>

<p>Thalassaemia intermedia is a highly variable condition. Although some cases are transfusion-dependent it is usually a less severe disease than β thalassaemia major.</p>

<h2>
<span class="number">5. </span>Screening support service</h2>

<p>Laboratories may have questions about screening policy or interpretation of results that cannot be answered easily by reference to this handbook or textbooks.</p>

<p>Oxford University Hospitals NHS Trust provides a support service for screening laboratories via designated telephone helplines and secure email. The national <abbr title="sickle cell and thalassaemia">SCT</abbr> screening programme commissions this service, which supports both antenatal and newborn screening inquiries.</p>

<p>Telephone: 01865 572 769
<br>
Email: <a class="govuk-link" href="mailto:lab.support@nhs.net">lab.support@nhs.net</a></p>

<div class="footnotes" role="doc-endnotes">
  <ol>
    <li role="doc-endnote">
      <p>Ryan K, Bain B, Worthington D, James J, Plews D, Mason A, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. British Journal of Haematology 2010: volume 149, pages 35 to 49&nbsp;<a aria-label="go to where this is referenced" class="govuk-link" href="#fnref:1" role="doc-backlink">↩</a></p>
    </li>
  </ol>
</div>
</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>